Antibody–drug conjugates have emerged as a powerful tool ... Traditional ADCs are engineered with a DNA-damaging or microtubule-targeting agent tethered to a monoclonal antibody.

Chimera Biotec, founded in 2000 as a spin-off from academic research in Germany, has implemented its proprietary DNA-antibody conjugates within the highly innovative Imperacer product line ...

Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, ...

ABBV-154, an antibody-drug conjugate comprising adalimumab conjugated to a proprietary glucocorticoid receptor modulator, shows potential for extending flare-free periods in patients with ...

Recombinant antibodies are invented antibodies formed by using recombinant DNA technology. While traditional monoclonal ...

Valerio Therapeutics is ending all clinical trials, including an ongoing phase 1/2 study for its investigational “DNA decoy” ...

With a strong track record of innovation and quality, GBI supports the development of complex biologics, including monoclonal antibodies, conjugates, and other therapeutic modalities. For more ...

(“Innate” or the “Company”) will host an event for institutional investors and analysts dedicated to its Antibody-Drug Conjugate (ADC) strategy, and particularly Nectin-4, the target of ...

The European Medicines Agency has recommended three new medicines to treat breast and cervical cancer and chemotherapy-induced neutropenia.